MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
about
Characterization of DNA Methylation in Circulating Tumor CellsThe prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients' survival: a meta-analysisClinical outcome of an alternative fotemustine schedule in elderly patients with recurrent glioblastoma: a mono-institutional retrospective study.The rs16906252:C>T SNP is not associated with increased overall survival or temozolomide response in a Han-Chinese glioma cohort.MGMT testing allows for personalised therapy in the temozolomide era.Laser Ablation of Recurrent Malignant Gliomas: Current Status and Future Perspective.Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trialLong-term survival in glioblastoma: methyl guanine methyl transferase (MGMT) promoter methylation as independent favourable prognostic factor.Phase I/II Study of Temozolomide Plus Nimustine Chemotherapy for Recurrent Malignant Gliomas: Kyoto Neuro-oncology Group.PITX2 and PANCR DNA methylation predicts overall survival in patients with head and neck squamous cell carcinomaRecent advances in targeted therapy for glioblastoma.Molecularly based management of gliomas in clinical practice.The efficacy and safety of various dose-dense regimens of temozolomide for recurrent high-grade glioma: a systematic review with meta-analysis.Experimental Therapeutic Trial Design for Pediatric Brain Tumors.The Diagnostic Use of Immunohistochemical Surrogates for Signature Molecular Genetic Alterations in Gliomas.CpG promoter methylation of the ALKBH3 alkylation repair gene in breast cancer.Re-irradiation after gross total resection of recurrent glioblastoma : Spatial pattern of recurrence and a review of the literature as a basis for target volume definition.Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives.Advances in the molecular genetics of gliomas - implications for classification and therapy.Outcome in unresectable glioblastoma: MGMT promoter methylation makes the difference.Pharmacotherapies for the treatment of glioblastoma - current evidence and perspectives.Relapsed Glioblastoma: Treatment Strategies for Initial and Subsequent Recurrences.Role of MGMT Methylation Status at Time of Diagnosis and Recurrence for Patients with Glioblastoma: Clinical Implications.The Role of Molecular Diagnostics in the Management of Patients with Gliomas.Low-grade epilepsy-associated neuroepithelial tumours - the 2016 WHO classification.Management of Elderly Patients with Glioblastoma.Alisertib demonstrates significant antitumor activity in bevacizumab resistant, patient derived orthotopic models of glioblastoma.The evolving role for re-irradiation in the management of recurrent grade 4 glioma.Angiogenesis inhibitors in tackling recurrent glioblastoma.Recurrent glioblastoma: who receives tumor specific treatment and how often?Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis.AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma.Clinical Applications of Contrast-Enhanced Perfusion MRI Techniques in Gliomas: Recent Advances and Current Challenges.Radiologic progression of glioblastoma under therapy - an exploratory analysis of AVAglio.Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma.Glioblastoma in elderly patients: solid conclusions built on shifting sand?From imaging to biology of glioblastoma: new clinical oncology perspectives to the problem of local recurrence.Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.Radiomics signature: A potential biomarker for the prediction of MGMT promoter methylation in glioblastoma.Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series.
P2860
Q26778427-7E36CBCD-F8C0-4ED6-8015-32A7E2D25912Q28074595-93A606EF-43E0-451D-A310-5C4F56C83819Q33432135-9D4CA2FC-9D3C-480F-BB6C-E4F6BB9FB736Q33757960-2B0EA8D0-A262-4A41-A446-425AEFC6266BQ35827916-9A805108-CDD8-46A4-AF04-AD6A5CCD8FC0Q36196954-9F3FC8FB-A35E-4880-9CD9-F9693378E5FCQ36705933-0AEFA7FD-6A4C-4C85-9C2A-1DD647D1FB72Q37432015-6B8D1315-0A67-4B22-9242-6F22CBFD7DABQ37592456-19A410B4-0B1F-4211-830F-6E9424FD2C14Q37689028-560D1245-4914-4AE0-A8CA-F3B056031820Q38539386-B61477D2-AFB6-4570-AFAE-7E34108A4D7FQ38551010-C139B32F-6BEB-4B73-8A57-0D96A5DCD619Q38579564-3A54AF81-15AE-4714-9F61-CBFB270D33BCQ38583655-81D87F32-605C-43BD-9D03-A23373B5BC94Q38670567-8B6838A8-1B70-4C97-AEBA-5A03558AA27FQ38692509-E1753A32-29F8-4801-9A32-A9D0468BB182Q38724867-4D4C8098-4001-4211-82CF-5E90E338A852Q38743138-18702C75-E90E-4382-AEB8-1DC2964BDEDDQ38777058-756A74D8-063D-4341-95C2-D75D9EF99FE4Q38786758-D81CE921-F9CB-470E-9DA1-79FBC26FF8E0Q38800041-AADF9AF3-67DF-43AD-B02A-2F5EF6DA830CQ38909395-7803DA2C-BD39-4EF1-8BC4-7892495405B0Q38919700-250EA3E8-9EDA-4424-8DAF-15E1CE36633DQ38921975-6E54291E-BD5A-448D-ADD5-E170E73DFEA3Q39011462-B69C8DD0-F537-40B7-B413-9943B2879A33Q39190627-65628012-64AA-4931-9010-DF5D69BA3BEDQ39211981-29B50D37-E9DB-4551-A205-BEA695B95E6EQ39225727-9F5802B2-CCF3-42C6-94E4-38A8B8C438D5Q39259089-4F7517DB-17B4-4134-8DE4-1E97B61B1EBFQ39975103-66304224-EAD5-49CA-A3C0-6FB5DA750594Q40113860-5DB8DB71-BC81-480E-B78C-EE07F2693832Q41139015-F1964005-D586-47CB-B7CD-8E7FBA579672Q43376098-E53A4E3A-45B6-4AC4-A72B-FFE74A0E94DFQ46410971-7B7510B3-8217-48FC-8F06-B34BCB0D9B39Q47655431-54528814-0D34-400B-8009-583E2ABB7774Q47827482-921015B9-E74D-4FD1-AAE7-B26FFD59DFB5Q47863423-0136DBE1-C22B-4F47-AA03-2B679167E752Q47903338-C966F9FD-95B2-45A6-9BFF-81E885014299Q47962003-20F2A551-19BE-43DA-A6D0-15BE5798F326Q48149391-6AE9147C-7FA8-493A-B828-8FC9FCA19CD9
P2860
MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
MGMT Promoter Methylation Is a ...... oblastoma: The DIRECTOR Trial.
@en
MGMT Promoter Methylation Is a ...... oblastoma: The DIRECTOR Trial.
@nl
type
label
MGMT Promoter Methylation Is a ...... oblastoma: The DIRECTOR Trial.
@en
MGMT Promoter Methylation Is a ...... oblastoma: The DIRECTOR Trial.
@nl
prefLabel
MGMT Promoter Methylation Is a ...... oblastoma: The DIRECTOR Trial.
@en
MGMT Promoter Methylation Is a ...... oblastoma: The DIRECTOR Trial.
@nl
P2093
P50
P1476
MGMT Promoter Methylation Is a ...... oblastoma: The DIRECTOR Trial.
@en
P2093
Antje Wick
Bärbel Kästner
Christine Marosi
DIRECTOR Study Group
Guido Nikkhah
Hans-Georg Wirsching
Joachim P Steinbach
Johannes Hüsing
Josef Pichler
Jörg C Tonn
P304
P356
10.1158/1078-0432.CCR-14-2737
P407
P50
P577
2015-02-05T00:00:00Z